

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

THIRD SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION IN RELATION TO ACQUISITION OF 19% EQUITY INTEREST OF THE TARGET COMPANY AND PROVISION OF LOAN

Reference is made to the announcements of Huakang Biomedical Holdings Company Limited (the “**Company**”) dated 6 January 2023, 7 February 2023 and 9 February 2023 (the “**Announcements**”) in respect of the Transactions involving the Sale and Purchase Agreement and Loan Agreement. Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

SECOND SUPPLEMENTAL SALE AND PURCHASE AGREEMENT

As disclosed in the announcement of the Company dated 9 February 2023, Huakang SZ and the Vendor entered into the Supplemental Sale and Purchase Agreement, pursuant to which Huakang SZ and the Vendor guaranteed that certain conditions (the “**Conditions**”) shall be fulfilled on or before 30 June 2023.

As further time is required for fulfilling the Conditions, on 30 June 2023 (after trading hours), Huakang SZ and the Vendor entered into a second supplemental agreement to the Sale and Purchase Agreement (the “**Second Supplemental Sale and Purchase Agreement**”), pursuant to which, it was agreed that the date which the Conditions shall be fulfilled be changed from “on or before 30 June 2023” to “on or before 31 December 2023.”

Save as amended and supplemented by the Second Supplemental Sale and Purchase Agreement, all other terms, conditions and provision in the Sale and Purchase Agreement (as revised and supplemented by the Supplemental Sale and Purchase Agreement) shall remain unchanged and shall continue to have full force and full legal effect.

REASONS FOR ENTERING OF THE SECOND SUPPLEMENTAL SALE AND PURCHASE AGREEMENT

The Target Company and the University have been in negotiation in relation to the terms of the Cooperation Agreement which has taken a longer time than expected, and the Target Company and the University have yet to enter into the Cooperation Agreement as of the date of this announcement. For these reasons, Huakang SZ and the Vendor have entered into the Second Supplemental Sale and Purchase Agreement to extend the period for the fulfilment of the Conditions.

The terms of the Second Supplemental Sale and Purchase Agreement were arrived at after arm’s length negotiations among Huakang SZ and the Vendor, and the Directors consider that the terms of the Second Supplemental Sale and Purchase Agreement are fair and reasonable and in the interest of the Company and the Shareholders as a whole.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 30 June 2023

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.